FrancophonIA/ELRC3.0 huggingface dataset:
English: chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in swallowing, collapse - movement disorders, paralysis, twitching - vertigo - hearing loss, deafness - disorders that affect your lungs, preventing your body from getting enough oxygen.
Croatian: bol ili stezanje u prsnom košu i/ili osjećaj omaglice/nesvjestice, teški oblik svrbeža kože ili izbočine na koži, oticanje lica, usnica, jezika i /ili grla, što može izazvati otežano gutanje, kolaps - poremećaji pokreta, paraliza, trzanje mišića
English: Mild
Croatian: vrijednosta
English: Bortezomib is a cytotoxic agent.
Croatian: Bortezomib je citotoksično sredstvo.
English: CI=confidence interval; CR=complete response; nCR=near complete response; ITT=intent to treat; RR=response rate; Bzmb=bortezomib; BzmbTDx=bortezomib, thalidomide, dexamethasone; TDx=thalidomide, dexamethasone; PR=partial response;
Croatian: CI= interval pouzdanosti; CR=kompletni odgovor; nCR=blizu kompletnog odgovora; ITT=populacija bolesnika uključenih u ispitivanje; RR=stopa odgovora; Bzmb=bortezomib; BzmbTDx=bortezomib, talidomid, deksametazon; TDx=talidomid, deksametazon; PR=Djelomični odgovor; OR=Omjer izgleda *Primarna mjera ishoda a OR za stope odgovora temeljeno na Mantel-Haenszel procjeni zajedničkog omjera izlgleda za stratificirane tablice; p vrijednosti Cochran Mantel-Haenszelovog testa.
English: When Bortezomib SUN is given in combination with other medicinal products, refer to their Summaries of Product Characteristics for additional contraindications.
Croatian: Kada se Bortezomib SUN primjenjuje u kombinaciji s drugim lijekovima, za dodatne kontraindikacije pogledajte Sažetke opisa svojstava lijeka tih lijekova.
English: Then, Bortezomib SUN may be reinitiated at a dose reduced by one dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2).
Croatian: Potom se ponovno može uvesti liječenje Bortezomib SUN-om u dozi smanjenoj za jednu razinu (s 1,3 mg/m2 na 1 mg/m2 ili s 1 mg/m2 na 0,7 mg/m2).
English: What Bortezomib SUN looks like and contents of the pack Bortezomib SUN 3.5 mg powder for solution for injection is a white to off-white powder or cake.
Croatian: Bortezomib SUN 3,5 mg prašak za otopinu za injekciju je bijeli do gotovo bijeli kolačić ili prašak.
English: How to store Bortezomib SUN
Croatian: Kako čuvati Bortezomib SUN
English: 1.2 Before administration, visually inspect the solution for particulate matter and discolouration.
Croatian: Prije primjene, otopinu treba vizualno pregledati na prisutnost stranih čestica i promjenu boje.
English: Common Gastrointestinal haemorrhage (inc mucosal)*, Dyspepsia, Stomatitis*, Abdominal distension, Oropharyngeal pain*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder*, Flatulence
Croatian: Gastrointestinalno krvarenje (uključujući mukozno)*, dispepsija, stomatitis*, distenzija abdomena, orofaringealna bol*, bolovi u abdomenu (uključujući gastrointestinalnu bol i bol slezene)*, poremećaj u ustima*, flatulencija
English: In study LYM-3002 in which bortezomib was administered with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CAP), the incidence of peripheral neuropathy in the combination regimens is presented in the table below:
Croatian: U ispitivanju LYM-3002 u kojem je bortezomib primijenjen s rituksimabom, ciklofosfamidom, doksorubicinom i prednizonom (R-CAP), incidencija periferne neuropatije u kombiniranim režimima prikazana je u tablici ispod: Tablica 10: Incidencija periferne neuropatije u ispitivanju LYM-3002 prema toksičnosti i prekidu liječenja radi periferne neuropatije
English: Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Croatian: Bortezomib SUN je indiciran u kombinaciji s deksametazonom ili s deksametazonom i talidomidom kao uvodno liječenje odraslih bolesnika s prethodno neliječenim multiplim mijelomom za koje je prikladna kemoterapija u visokim dozama s transplantacijom hematopoetskih matičnih stanica.
English: In Cycles 5-9, Bortezomib SUN is administered once weekly on days 1, 8, 22 and 29.
Croatian: Od 5. do 9. ciklusa Bortezomib SUN se primjenjuje jednom tjedno, na 1., 8., 22. i 29. dan.
English: Bortezomib was positive for clastogenic activity (structural chromosomal aberrations) in the in vitro chromosomal aberration assay using Chinese hamster ovary (CHO) cells at concentrations as low as 3.125 μg/ml, which was the lowest concentration evaluated.
Croatian: Pri koncentracijama od samo 3,125 μg/ml, što je bila najniža koncentracija koja se ispitivala, bortezomib je pokazao klastogenu aktivnost (strukturalne kromosomske aberacije) u in vitro testu kromosomske aberacije na stanicama jajnika kineskog hrčka (CHO od engl.
English: The vial is contained in a transparent blister pack consisting of a tray with a lid. Each pack contains 1 single-use vial.
Croatian: Bočica se nalazi u prozirnom blister pakiranju koje se sastoji od podloška i poklopca.
English: Common side effects (may affect up to 1 in 10 people) - shingles (localized including around the eyes or spread across the body) - herpes virus infections - bacterial and viral infections - respiratory infections, bronchitis, coughing with phlegm, flu like illness - fungal infections - hypersensitivity (allergic reaction) - inability to produce enough insulin or resistance to normal levels of insulin - fluid retention - difficulty or problems in sleeping - loss of consciousness - altered level of consciousness, confusion - feeling dizzy - increased heartbeat, high blood pressure, sweating - abnormal vision, blurred vision - heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate - high or low blood pressure - sudden fall of blood pressure upon standing which may lead to fainting - shortness of breath with exercise - cough - hiccups - ringing in the ears, ear discomfort - bleeding from your bowels or stomach - heartburn - stomach pain, bloating - difficulty swallowing - infection or inflammation of the stomach and intestines - stomach pain - sore mouth or lip, throat pain - alteration of liver function - itching of skin - redness of skin - rash - muscle spasms - infection of the urinary tract - pain in limbs
Croatian: Česte nuspojave (mogu se javiti u do 1 na 10 osoba) - herpes zoster (lokalizirano, uključujući područje oko očiju ili prošireno po cijelom tijelu) - infekcije virusom herpesa - bakterijske i virusne infekcije - infekcije dišnog sustava, bronhitis, iskašljavanje sluzi, bolest nalik gripi - gljivične infekcije - preosjetljivost (alergijska reakcija) - nemogućnost stvaranja dovoljno inzulina ili rezistencija na normalne razine inzulina - zadržavanje tekućine - poteškoće ili problemi sa spavanjem - gubitak svijesti - promijenjena razina svijesti, smetenost - osjećaj omaglice - ubrzani otkucaji srca, visoki krvni tlak, znojenje - poremećaj vida, zamagljen vid - zatajenje srca, srčani udar, bol u prsnom košu, nelagoda u prsnom košu, ubrzan ili usporen puls - visoki ili niski krvni tlak - nagli pad krvnog tlaka pri ustajanju, što može dovesti do nesvjestice - nedostatak zraka pri tjelesnom naporu
English: Prednisone is administered orally at 100 mg/m2 on days 1, 2, 3, 4 and 5 of each Bortezomib SUN treatment cycle.
Croatian: Prednizon se primjenjuje peroralno, 100 mg/m2 1., 2., 3., 4. i 5. dan svakog ciklusa liječenja
English: Reduce Bortezomib SUN to 0.7 mg/m2 in the first treatment cycle.
Croatian: U prvom ciklusu liječenja smanjiti dozu Bortezomib SUN-a na 0,7 mg/m2.
English: Pegylated liposomal doxorubicin 30 mg/m2 is given on day 4 of the Bortezomib SUN 21-day treatment cycle as an intravenous infusion after the Bortezomib SUN injection.
Croatian: Pegilirani liposomalni doksorubicin u dozi od 30 mg/m2 daje se kao infuzija u venu nakon injekcije Bortezomib SUN-a, na 4. dan ciklusa liječenja koji traje 21 dan.
English: Hepatic impairment
Croatian: Iritacija mjehura
English: Therefore, this specific regimen with concomitant administration with high-dose cytarabine (2 g/m2 per day) by continuous infusion over 24 hours is not recommended.
Croatian: (2 g/m2 na dan) kontinuiranom infuzijom u trajanju od 24 sata.
English: bleeding of the eye - swelling of your lymph glands - joint or muscle stiffness, sense of heaviness, pain in your groin - hair loss and abnormal hair texture - allergic reactions - redness or pain at the injection site - mouth pain - infections or inflammation of the mouth, mouth ulcers, oesophagus, stomach and intestines,
Croatian: - zvonjava u ušima, nelagoda u uhu - krvarenje iz crijeva ili iz želuca - žgaravica - bol u želucu, nadutost - otežano gutanje - infekcija ili upala želuca i crijeva - bol u želucu - rane na ustima ili na usnama, grlobolja
English: Discontinue Bortezomib SUN
Croatian: Prekinuti primjenu Bortezomib SUN-a
English: Posology for previously untreated multiple myeloma patients not eligible for haematopoietic stem cell transplantation
Croatian: Doziranje kod bolesnika s prethodno neliječenim multiplim mijelomom za koje transplantacija hematopoetskih matičnih stanica nije prikladna
English: Therefore, caution should be used during handling and preparation of Bortezomib SUN. Use of gloves and other protective clothing to prevent skin contact is recommended.
Croatian: Preporučuje se nošenje rukavica i druge zaštitne odjeće kako bi se sprječio dodir s kožom.
English: Intrathecal administration
Croatian: Intratekalna primjena
English: Discontinue bortezomib if PML is diagnosed.
Croatian: Ako je dijagnosticiran PML, liječenje bortezomibom treba prekinuti.
English: RECONSTITUTION FOR INTRAVENOUS INJECTION
Croatian: PRIPREMA LIJEKA (REKONSTITUCIJA) ZA PRIMJENU INTRAVENSKOM INJEKCIJOM
English: Incidence Adverse reaction
Croatian: Incidencija Nuspojava
English: If you are given Bortezomib SUN for the treatment of multiple myeloma the side effects you may get are listed below:
Croatian: Ako Bortezomib SUN primate za liječenje multiplog mijeloma mogu
English: Uncommon Renal failure acute, Renal failure chronic*, Urinary tract infection*, Urinary tract signs and symptoms*, Haematuria*, Urinary retention, Micturition disorder*, Proteinuria, Azotaemia, Oliguria*, Pollakiuria
Croatian: Manje često Akutno zatajenje bubrega, kronično zatajenje bubrega*, infekcija mokraćnog sustava*, znakovi i simptomi mokraćnog sustava*, hematurija*, retencija mokraće, poremećaj mokrenja*, proteinurija, azotemija, oligurija*,
English: Common Sleep disorders and disturbances* Nervous system disorders Very Common
Croatian: Poremećaji i smetnje spavanja*
English: Bortezomib SUN is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle.
Croatian: Bortezomib SUN se primjenjuje putem intravenske ili supkutane injekcije u preporučenoj dozi od 1,3 mg/m2 površine tijela, dva puta tjedno tijekom dva tjedna, 1., 4., 8. i 11. dana, u ciklusu liječenja od 21 dan.
English: Pneumonia*
Croatian: Vrlo često Pneumonija*
English: breathing that becomes shallow, difficult or stops, wheezing - blood clots in your lungs - yellow discoloration of the eyes and skin (jaundice) - lump in the eyelid (chalazion), red and swollen eyelids.
Croatian: Neki od slučajeva uključuju otežano disanje, nedostatak zraka, nedostatak zraka u stanju bez napora, disanje koje postaje plitko, teško ili prestaje, piskanje - krvni ugrušci u plućima - žućkasta boja očiju i kože (žutica) - kvržica na kapku (halacion), crveni i otečeni kapci.
English: A hazard ratio < 1 indicates an advantage for BzmbR-CAP. c Based on Kaplan-Meier product limit estimates.
Croatian: Omjer hazarda manji od 1 pokazuje da VMP ima prednost c Nominalna p-vrijednost utemeljena na stratificiranom log-rank testu prilagođenom za čimbenike stratifikacije: β2
English: • Reconstitution, dosing and administration booklet
Croatian: • Brošura s uputstvima za rekonstituciju, doziranje i primjenu lijeka
English: Common Weight decreased Uncommon Hyperbilirubinaemia*, Protein analyses abnormal*, Weight increased, Blood test abnormal*, C-reactive protein increased
Croatian: povećana težina, abnormalan krvni nalaz*, povišen C
English: Table 2: Recommended posology for Bortezomib SUN in combination with melphalan and prednisone Twice weekly Bortezomib SUN (cycles 1-4)
Croatian: Tablica 2: Preporučeno doziranje Bortezomib SUN-a kada se primjenjuje u kombinaciji s melfalanom i prednizonom
English: Thrombocytopenia*, Neutropenia*, Anaemia* Common Leukopenia*, Lymphopenia* Uncommon Pancytopenia*, Febrile neutropenia, Coagulopathy*, Leukocytosis*, Lymphadenopathy, Haemolytic anaemia#
Croatian: Leukopenija*, limfopenija * Manje često Pancitopenija*, febrilna neutropenija, koagulopatija*,
English: CRf n (%)
Croatian: CRf n (%) PRf n (%)
English: When toxicity resolves re-initiate Bortezomib SUN treatment and reduce dose to 0.7 mg/m2 once per week.
Croatian: Kad se toksičnost povuče, ponovno uvesti liječenje Bortezomib SUN-om i smanjiti dozu na
English: Dexamethasone 20 mg is given orally on days 1, 2, 4, 5, 8, 9, 11, and 12, of the Bortezomib SUN 21-day treatment cycle.
Croatian: Deksametazon od 20 mg se primjenjuje oralno 1., 2., 4., 5., 8., 9., 11. i 12. dan tijekom ciklusa liječenja Bortezomib SUN-om.
English: Nausea and vomiting symptoms*, Diarrhoea*, Constipation
Croatian: Vrlo često Mučnina i simptomi povraćanja*, proljev*, konstipacija Često
English: NAME OF THE MEDICINAL PRODUCT Bortezomib SUN 3.5 mg powder for solution for injection
Croatian: Bortezomib SUN 3,5 mg prašak za otopinu za injekciju
English: Mantle cell lymphoma
Croatian: Limfom plaštenih stanica (MCL)
English: Combination therapy with dexamethasone and thalidomide Bortezomib SUN is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 28-day treatment cycle.
Croatian: Kombinirano liječenje uz deksametazon i talidomid Bortezomib SUN se primjenjuje putem intravenske ili supkutane injekcije u preporučenoj dozi od 1,3 mg/m2 površine tijela, dva puta tjedno tijekom dva tjedna, 1., 4., 8. i 11. dana, u ciklusu liječenja od 28 dana.
English: Patients in the BzmbR-CAP treatment arm received bortezomib (1.3 mg/m2; on days 1, 4, 8, 11, rest period days 12-21), rituximab 375 mg/m2 IV on day 1; cyclophosphamide 750 mg/m2 IV on day 1; doxorubicin 50 mg/m2 IV on day 1; and prednisone 100 mg/m2 orally on day 1 through day 5 of the 21 day bortezomib treatment cycle.
Croatian: dan; ciklofosfamid 750 mg/m2 i.v. 1. dan; doksorubicin 50 mg/m2 i.v. 1. dan i prednizon 100 mg/m2 peroralno 1. do 5. dan 21-dnevnog ciklusa liječenja bortezomibom.
English: 19.2 mo
Croatian: 19,2 mjeseci
English: Mediana (95% CI)
Croatian: TTP, dani (95 % CI)
English: Intent to Treat Populationb n=74
Croatian: nCR n (%) Populacija uključena u ispitivanjeb n=74
English: You should tell your doctor if you have any of the following: - low numbers of red or white blood cells - bleeding problems and/or low number of platelets in your blood - diarrhoea, constipation, nausea or vomiting - fainting, dizziness or light-headedness in the past - kidney problems - moderate to severe liver problems - numbness, tingling, or pain in the hands or feet (neuropathy) in the past - heart or blood pressure problems - shortness of breath or cough - seizures - shingles (localised including around the eyes or spread across the body) - symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion,
Croatian: Ako imate nešto od sljedećeg, morate o tome obavijestiti svog liječnika: - snižen broj crvenih ili bijelih krvnih stanica - tegobe s krvarenjem i/ili snižen broj krvnih pločica - proljev, zatvor, mučninu ili povraćanje - nesvjesticu, omaglicu ili ošamućenost u prošlosti - tegobe s bubrezima
English: Atrial flutter, Myocardial infarction*, Atrioventricular
Croatian: Oticanje oka*, abnormalan vid*, konjunktivitis*
English: In the Phase III study in patients with previously untreated multiple myeloma, the overall incidence of herpes zoster reactivation was more common in patients treated with Bortezomib+Melphalan+Prednisone compared with Melphalan+Prednisone (14% versus 4% respectively).
Croatian: + melfalan + prednizon nego u onih koji su primali melfalan + prednizon (14 % naspram 4 %).
English: There have been fatal cases of inadvertent intrathecal administration of bortezomib.
Croatian: Nenamjerna intratekalna primjena bortezomiba dovela je do smrtnih slučajeva.
English: Haematological toxicity
Croatian: Hematološka toksičnost tijekom ciklusa
English: If any discolouration or particulate matter is observed, the solution should be discarded.
Croatian: Ako se uoči promjena boje ili prisutnost stranih čestica, otopinu je potrebno prikladno zbrinuti.
English: breathing that becomes shallow, difficult or stops, wheezing - hiccups, speech disorders - increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention - altered levels of consciousness, confusion, memory impairment or loss - hypersensitivity - hearing loss, deafness or ringing in the ears, ear discomfort - hormone abnormality which may affect salt and water absorption - overactive thyroid gland - inability to produce enough insulin or resistance to normal levels of insulin - irritated or inflamed eyes, excessively wet eyes, painful eyes, dry eyes, eye infections, lump in the eyelid (chalazion), red and swollen eyelids, discharge from the eyes, abnormal vision,
Croatian: Neki od slučajeva uključuju otežano disanje, nedostatak zraka, nedostatak zraka u stanju bez napora, disanje koje postaje plitko, teško ili prestaje, piskanje - štucanje, poremećaj govora - pojačana ili smanjena proizvodnja mokraće (zbog oštećenja bubrega), bolno mokrenje ili krv/bjelančevine u mokraći, zadržavanje tekućine - promijenjene razine svijesti, smetenost, oštećenje ili gubitak pamćenja - preosjetljivost - nagluhost, gluhoća ili zvonjenje u ušima, nelagoda u uhu - poremećaj hormona koji može utjecati na apsorpciju soli i vode - prekomjerna aktivnost štitnjače - nemogućnost stvaranja dovoljno inzulina ili rezistencija na normalne razine inzulina - nadražene ili upaljene oči, pretjerano vlaženje očiju, bol u oku, suhe oči, infekcije oka, kvržica na kapku (halacion), crveni i otečeni kapci, iscjedak iz očiju, poremećaj vida, krvarenje oka - oticanje limfnih žlijezda - ukočenost zglobova ili mišića, osjećaj težine, bol u preponama - gubitak kose i neuobičajena tekstura dlake - alergijske reakcije - crvenilo ili bol na mjestu primjene injekcije - bol u ustima - infekcije ili upale u ustima, čirevi u ustima, jednjaku, želucu i crijevima, ponekad povezani s bolovima ili krvarenjem, slabe kretnje crijeva (uključujući začepljenje), nelagodom u trbuhu ili jednjaku, otežanim gutanjem, povraćanjem krvi - kožne infekcije - bakterijske i virusne infekcije
English: Common Gastrointestinal haemorrhage (inc mucosal)*, Abdominal distension, Dyspepsia, Oropharyngeal pain*, Gastritis*, Oral ulceration*, Abdominal discomfort, Dysphagia, Gastrointestinal inflammation*, Abdominal pain (inc gastrointestinal and splenic pain)*, Oral disorder* Uncommon Colitis (inc clostridium difficile)* Hepatobiliary disorders Common Hepatotoxicity (inc liver disorder) Uncommon Hepatic failure
Croatian: Gastrointestinalno krvarenje (uključujući mukozno)*, distenzija abdomena, dispepsija, orofaringealna bol *, gastritis*, ulceracije u ustima*, nelagoda u abdomenu, disfagija, gastrointestinalna upala*, bol u abdomenu (uključujući gastrointestinalnu bol i bol slezene)*, poremećaj u ustima*
English: * Survival update based on a median duration of follow-up at 60.1 months mo: months
Croatian: EBMT kriteriji g Svi randomizirani bolesnici sa sekrecijskom bolešću * Ažurirano preživljenje na temelju medijana trajanja praćenja od 60,1 mjesec CI=Interval pouzdanosti
English: Class
Croatian: Serija
English: How Bortezomib SUN is given
Croatian: Kako se primjenjuje Bortezomib SUN
English: Efficacy endpoint
Croatian: Ishod djelotvornosti
English: Uncommon Pancreatitis (inc chronic)*, Haematemesis, Lip swelling*, Gastrointestinal obstruction (inc small intestinal obstruction, ileus)*, Abdominal discomfort, Oral ulceration*, Enteritis*, Gastritis*, Gingival bleeding, Gastrooesophageal reflux disease*, Colitis (inc clostridium difficile)*, Colitis ischaemic#, Gastrointestinal inflammation*, Dysphagia, Irritable bowel syndrome, Gastrointestinal disorder NOS, Tongue coated, Gastrointestinal motility disorder*, Salivary gland disorder*
Croatian: Incidencija Nuspojava krvarenje desni, gastroezofagealna refluksna bolest*, kolitis (uključujući clostridium difficile)*, ishemijski kolitis#, gastrointestinalna upala*, disfagija, sindrom iritabilnog crijeva, nespecificirani gastrointestinalni poremećaj, obložen jezik, poremećaj gastrointestinalne pokretljivosti*, poremećaj žlijezda slinovnica*
English: Thrombocytopenia*, Febrile neutropenia, Neutropenia*, Leukopenia*, Anaemia*, Lymphopenia* Uncommon Pancytopenia*
Croatian: leukopenija*, anemija*, limfopenija* Manje često Pancitopenija*
English: When Bortezomib SUN is given in combination with other medicinal products, refer to the Summary of Product Characteristics of these products for instructions for administration.
Croatian: Kada se Bortezomib SUN daje u kombinaciji s drugim lijekovima, za upute o primjeni tih lijekova pogledajte njihov Sažetak opisa svojstava lijeka.
English: Decreased appetite Common Hypokalaemia*, Blood glucose abnormal*, Hyponatraemia*, Diabetes mellitus*, Fluid retention Uncommon Tumour lysis syndrome
Croatian: Hipokalijemija *, abnormalna vrijednost glukoze u krvi *, hiponatrijemija*, dijabetes melitus*, retencija tekućine
English: Combination therapy with pegylated liposomal doxorubicin Bortezomib SUN is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11 in a 21-day treatment cycle.
Croatian: Kombinirano liječenje s pegiliranim liposomalnim doksorubicinom Bortezomib SUN se primjenjuje putem intravenske ili supkutane injekcije u preporučenoj dozi od 1,3 mg/m2 površine tijela, dva puta tjedno tijekom dva tjedna, 1., 4., 8. i 11. dana, u ciklusu liječenja od 21 dan.
English: Incidence Adverse reaction Inflammation, Injection site phlebitis*, Tenderness, Ulcer, Irritability, Non-cardiac chest pain, Catheter site pain, Sensation of foreign body
Croatian: Smrt (uključujući iznenadnu), multiorgansko zatajenje, krvarenje na mjestu injiciranja*, hernija (uključujući hijatus)*, poremećaj cijeljenja*, upala, flebitis na mjestu injiciranja*, osjetljivost, ulkus, iritabilnost, bol u prsištu ne-srčanog porijekla, bol na mjestu katetera, osjećaj stranog tijela
English: Dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib SUN 21-day treatment cycle.
Croatian: Deksametazon od 40 mg se primjenjuje oralno 1., 2., 3., 4., 8., 9., 10. i 11. dan tijekom ciklusa liječenja Bortezomib SUN-om.
English: Posology for patients with previously untreated mantle cell lymphoma (MCL) Combination therapy with rituximab, cyclophosphamide, doxorubicin and prednisone (BzmbR-CAP) Bortezomib SUN is administered via intravenous or subcutaneous injection at the recommended dose of 1.3 mg/m2 body surface area twice weekly for two weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21.
Croatian: Kombinirano liječenje uz rituksimab, ciklofosfamid doksorubicin i prednizon (BzmbR-CAP) Bortezomib SUN se primjenjuje putem intravenske injekcije u preporučenoj dozi od 1,3 mg/m2 površine tijela, dva puta tjedno tijekom dva tjedna 1., 4., 8. i 11. dana, nakon čega slijedi period odmora od 10 dana tijekom 12. - 21. dana.